SPAC season is back as Arbor Rapha Capital Bioholdings, a blank-check company, lands on the public markets today to raise $150 million for a future biopharma merger. By Kyle LaHucik | Oct 29, 2021 10:15am | FierceBiotech
New deal with Takeda could mean up to $3.6 billion in milestone payments.